1. Navigate to /scrip
  2. Navigate to /scrip/business
  3. Navigate to /scrip/business/stock-watch

Stock Watch: GLP-1 Expectations Dashed

Pfizer’s Foray Into Obesity Slims Down As Tolerability Becomes The New Battleground

 
• By Andy Smith
  
Generate a summary of this article
Listen to this article
Beta

If oral GLP-1 agonists are going to be successful in a wider weight loss indication, lower efficacy may be the trade-off for better tolerability in this bigger and more healthy population.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The title of a note on Pfizer Inc.* by the analysts at J.P. Morgan in late November included the question “Where Is The Bottom?” – referring to its stock price. At that time, Pfizer’s stock price had fallen in the year to the end of November by over 40%. This compared with an 11-month gain of just over 2% for the NYSE Arca Pharmaceutical Index (DRG). Among the list of Pfizer’s key pipeline assets highlighted in the note was the oral GLP-1 agonist danuglipron where the J.P. Morgan analysts saw “a favorable risk/reward into ph2 data” as Pfizer attempted to encroach on Novo Nordisk A/Ss and Eli Lilly and Company’s market for GLP-1 agonists in diabetes and obesity.

Expectations for the Phase II study of danuglipron had been running high long before the licensing of another oral GLP-1...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

Article Without An Author Listed

Here is a short description.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Stock Watch: When Development Goes Too Far

 
• By Andy Smith

R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.

Stock Watch: Bad Deals Backfire On Bayer And CSL

 
• By Andy Smith

As the pharma earnings season wrapped up, it seemed like a contest to see which company's stock price dropped the most after their announcement and which made the poorest acquisition.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.